Click here to access Business Weekly's ten year archive of East of England 'Life Sciences' articles
|
|
Antisoma shifts key London capability to new facility at Hertfordshire BioPark |
|
Written by Lautaro Vargas
|
|
Wednesday, 30 April 2008 |
|
The legacy left by Swiss pharma giant, Roche, in the region continues
with the decision by anti-cancer drug developer, Antisoma, to relocate
its pre and nonclinical operations at the Hertfordshire BioPark in
Welwyn Garden City.
|
|
|
Japanese pharmaceutical firm axeing Cambridge jobs |
|
Written by Lautaro Vargas
|
|
Wednesday, 30 April 2008 |
|
Japanese owned Sosei R & D Ltd could be moving out of Chesterford
Research Park in the search for smaller premises as the company makes
shock redundancies. A company source confirmed it is in the process of axeing several jobs,
though more detailed information couldn’t be given until completion of
a consulting period with staff.
|
|
|
NextGen in talks about sale of UK divisions |
|
Written by Lautaro Vargas
|
|
Wednesday, 30 April 2008 |
|
NextGen Sciences is in talks with a number of companies about the possibility of selling at least one of its three UK divisions following a strategic review that will see the company leave the UK for the US by the end of the year.
|
|
|
Cambridge biotech start-up secures £1million |
|
Written by News Desk
|
|
Thursday, 24 April 2008 |
Cambridge based Domainex, a biopharma spin-out from University College London, has raised £1 million from Longbow Capital LLP, which specialises in healthcare and technology investments, and The Capital Fund.
|
|
|
NextGen to quit the East of England for the US |
|
Written by Lautaro Vargas
|
|
Thursday, 24 April 2008 |
The NextGen Group in Cambridgeshire is severing its ties with the UK and moving out of the East of England by the end of the year.
|
|
|
Over a quarter wiped off Alizyme's shares |
|
Written by Lautaro Vargas
|
|
Wednesday, 23 April 2008 |
Over a quarter was wiped off Alizyme’s share price after
the Cambridge biotech announced it would discontinue development of its
irritable bowel syndrome (IBS) drug candidate, renzapride, following
Phase III results, which showed it had limited effects.
|
|
|
Acambis wins new $425 smallpox vaccine contract |
|
Written by Lautaro Vargas
|
|
Wednesday, 23 April 2008 |
 Acambis has won a $425m (£213m), 10-year contract to provide the US government with a warm-base manufacturing capability for the ACAM2000 smallpox vaccine, which it is currently stockpiling.
|
|
|
Linguamatics deepens relationship with Pfizer |
|
Written by News Desk
|
|
Thursday, 17 April 2008 |
Cambridge based Linguamatics has extended its collaboration with Pfizer in a deal of undisclosed value.
|
|
|
Evans: We are not turning our backs on biotech |
|
Written by Tony Quested
|
|
Wednesday, 16 April 2008 |
 In an exclusive interview with Business Weekly, Prof Sir Christopher Evans reveals some of his plans for the new Life Sciences investment house, Excalibur.
|
|
|
Heart products key to Cambridge University spin-out's IPO |
|
Written by Tony Quested
|
|
Wednesday, 16 April 2008 |
A Cambridge company is aiming to fill a global market void by creating
new health and medical food products designed to unclog blood vessels
and stave off heart disease – and push them through major pharmacies.
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 Next > End >>
|
| Results 35 - 51 of 140 |
Life Sciences 
